This retrospective study evaluates the efficacy and tolerability of anti-calcitonin gene-related peptide (CGRP) therapy—encompassing monoclonal antibodies and small-molecule antagonists—in treating resistant migraine in individuals aged 12 to 21. Here, CALCA is linked to migraine disorder.